Benchmark analyst Bruce Jackson lowered the firm’s price target on Biolase to $4 from $10 and keeps a Speculative Buy rating on the shares after lowering its EPS estimates following the completion of a unit offering of convertible preferred stock and warrants on Monday. Results from Part 2 of the McGuire Study, including the radiographic data, could be published later this year and provide a possible catalyst for the shares, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIOL:
- Biolase sees 2023 revenue growth of 15%-20%, consensus $60M
- Biolase reports Q2 EPS ($8.93), consensus ($5.33)
- BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR
- BioLase trading resumes
- BioLase trading halted, volatility trading pause
Questions or Comments about the article? Write to editor@tipranks.com